Recursion Merges with Exscientia to Accelerate Drug Discovery
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
- Latest
- Trending
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Discover Piper Sandler's eight high-quality defensive biotech stocks poised to thrive in volatile markets.
Natera Inc. sees a 58% revenue surge in Q2 2024, driven by high test volumes and ASP growth, raising guidance ...
23andMe's Q1 revenue declines by 34% but narrows losses. Focus on AI and genetic studies drives future growth.
Bruker sees strong growth in Q2 2024, with strategic acquisitions boosting revenues despite challenges in biopharma and Chinese markets.
Viatris Inc. reports $3.8B in Q2 revenue, boosts 2024 outlook with innovative pipeline progress and strategic investments.
Southern Miss advances biomaterials research for immune disease treatment with a $2.5M collaboration, boosting Mississippi's biotech.
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Canada allocates 12 million CAD to study oil sands' impact on Indigenous health, addressing pollution concerns.
Personalis sees 35% Q2 revenue growth, lifts full-year outlook to $79-$81M.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.